

Meeting note

Brief call with Sanofi on the health industrial ecosystem, 3 February 2022, 10:00-10:30

Sanofi: [REDACTED]

COM: Maurits-Jan Prinz (Cabinet of Commissioner Breton) [REDACTED] was also invited, but could not join)

- Sanofi presented its views in relation to the strategic autonomy of the health industry, referring to a recent article: <https://confrontations.org/wp-content/uploads/2022/02/05-133.pdf>. It highlighted its activities in the field of cell and gene therapy (which Sanofi described as addressing a major unmet medical need, while also involving a relatively high level of commercial risk), as well as its activities in the field of mRNA technology. Sanofi pointed out that some MS are actively investing in additional capacity (e.g.: <https://www.bmwi.de/Redaktion/EN/Pressemitteilungen/2022/20220101-funding-launched-for-speciality-lipids-used-as-key-components-of-mrna-vaccines.html>). Sanofi referred to the plans for an Important Project of Common European Interest (IPCEI) in the health sector. COM stressed that it is up to Member States to determine the scope of an IPCEI and to identify relevant projects. Italy is the latest Member State to launch a call for project in this context: <https://www.mise.gov.it/index.php/en/202-news-english/2043151-call-for-ipcei-on-health-now-open>.
- Sanofi commented on the Commission's Industry Forum, which was established under the revised Industry Strategy. Sanofi considered it important that the forum also captures experience from companies with an EU manufacturing presence (rather than only associations). Sanofi referred to the framework of sector strategic committees ("comités stratégiques de filière") in France. The work of this committee could also be relevant in the context of the Commission's Structured Dialogue on the security of medicines supply. COM asked Sanofi to share further information about this in writing.